title: Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines?
authors: Institut de Cardiologie, ACTION Group, INSERM CMR937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France; Service de Cardiologie, Hôpital Universitaire Carémeau, Nîmes, France; Université Montpellier 1, Montpellier, France.
authors: Guillaume
authors: G
authors: Cayla
authors: Institut de Cardiologie, ACTION Group, INSERM CMR937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France.
authors: Jean-Philippe
authors: JP
authors: Collet
authors: Institut de Cardiologie, ACTION Group, INSERM CMR937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France.
authors: Johanne
authors: J
authors: Silvain
authors: Institut de Cardiologie, ACTION Group, INSERM CMR937, Pitié-Salpêtrière Hospital (AP-HP), Université Paris 6, Paris, France. Electronic address: gilles.montalescot@psl.aphp.fr.
authors: Gilles
authors: G
authors: Montalescot
mesh_terms: D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D018579:Patient Selection; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D058925:Receptors, Purinergic P2Y12 / Q000097:blood / Q000187:drug effects*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12
keywords: Angioplastie percutanée coronaire; Antiplatelets; Clopidogrel; Coronarographie; Non–ST-elevation acute coronary syndromes; P2Y(12) inhibitors; Prasugrel; Pré-traitement